PMC:7073332 / 1186-1525
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
54 | 83-88 | Species | denotes | human | Tax:9606 |
55 | 322-327 | Species | denotes | human | Tax:9606 |
61 | 53-57 | Species | denotes | HCoV | Tax:694448 |
62 | 134-138 | Species | denotes | HCoV | Tax:694448 |
63 | 285-289 | Species | denotes | HCoV | Tax:694448 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T6 | 165-174 | Body_part | denotes | melatonin | http://purl.org/sig/ont/fma/fma74644 |
T7 | 265-269 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
T8 | 328-332 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 83-88 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T5 | 265-269 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
T6 | 322-338 | http://www.ebi.ac.uk/cellline#human_cell_line | denotes | human cell lines |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T15 | 36-40 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T16 | 152-157 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T17 | 165-174 | Chemical | denotes | melatonin | http://purl.obolibrary.org/obo/CHEBI_16796 |
T18 | 176-190 | Chemical | denotes | mercaptopurine | http://purl.obolibrary.org/obo/CHEBI_50667 |
T19 | 196-205 | Chemical | denotes | sirolimus | http://purl.obolibrary.org/obo/CHEBI_9168 |
T20 | 260-264 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 0-339 | Sentence | denotes | Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. |